February 4, 2022

February 4, 2022

CLL and the Emotional Impact of Watchful Waiting

The concept of just watching and waiting until ‘the enemy was ready to slay me’, then ‘go to war’, seemed a little antiquated.

February 4, 2022

FDA Places Partial Clinical Hold on Studies Featuring Umbralisib and Ublituximab in CLL and Non-Hodgkin Lymphoma

The combination of umbralisib plus ublituximab, often abbreviated to U2, has promising activity in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) as shown in this ASH 2021 abstract:

February 4, 2022

February 2022 CLL Bloodline

Over the course of a year of monthly meetings, the CLL Bloodline will teach the BASICS needed to understand CLL, bring news, help with the acronyms and new vocabulary, and offer simple fun quizzes. MONTHLY QUIZ: Chemo-immunotherapy (CIT), specifically FCR (fludarabine, cyclophosphamide, and rituximab), can give very long remissions

February 4, 2022

CLL and the Emotional Impact of Watchful Waiting

FDA Places Partial Clinical Hold on Studies Featuring Umbralisib and Ublituximab in CLL and Non-Hodgkin Lymphoma

February 2022 CLL Bloodline

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT